Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EPPENDORF AG

Eppendorf is a life science company that develops and sells instruments, consumables, and services for liquid-, sampl... read more Featured Products: More products

Download Mobile App




Molecular Testing Accuracy for Clostridium difficile Scrutinized

By LabMedica International staff writers
Posted on 31 Aug 2016
Print article
Image: The Mastercycler nexus thermal cycler (Photo courtesy of Eppendorf).
Image: The Mastercycler nexus thermal cycler (Photo courtesy of Eppendorf).
Accurate diagnosis of Clostridium difficile infection (CDI) is paramount for patient management and the wrong diagnosis places patients at risk, delays treatment, and/ or contributes to transmission of infection in the healthcare setting.

The selection of diagnostic tests to confirm CDI is controversial because of the variety of laboratory methods that are available and used across various facilities, and lack of standard recommendations for testing. Although amplification of the toxin B gene by polymerase chain reaction (PCR) is a sensitive method for detecting toxigenic C. difficile, false negative results still occur and could impact the diagnosis and treatment of this infection.

Scientists at the Northern Ontario School of Medicine (Sudbury, ON, Canada) and their colleagues tested stool samples from patients with diarrhea, and suspected of having CDI, were tested in the diagnostic laboratory for C. difficile using a PCR test and culture techniques. Multiplex PCR was performed on presumptive C. difficile isolates to detect the Toxin A gene (tcdA), Toxin B gene (tcdB), and the triose phosphate isomerase gene (tpi). The reactions were carried out in an Eppendorf Mastercycler nexus thermal cycler (Fisher Scientific, Ottawa, ON, Canada).

A total of 2,308 samples were tested for toxigenic C. difficile by GeneXpert C. difficile epi test (Cepheid, Sunnyvale, CA, USA) and culture methods over a 15-month period. The observed agreement of the results of the two tests was 95.1%. A total of 295 samples tested positive by GeneXpert, while 2,013 samples were negative by GeneXpert. C. difficile isolated from the discrepant samples resulted in diverse ribotyping patterns suggesting they were derived from different strains. The samples belonged to patients who were distributed evenly between age groups and wards in the hospital. In the majority of cases, the false negative C. difficile test results did not seem to impact the clinical outcome in these patients.

The authors concluded that although molecular methods are considered among the most sensitive methods available for clinical diagnosis of CDI, it seems inevitable that some cases, which are positive for C. difficile, might be missed when using this method, or any other method for that matter. Both clinical and analytical sensitivity of C. difficile tests should be considered when deciding which diagnostic assay to use, and clinical correlates should be examined carefully before excluding CDI as a cause of disease. The study was published on August 19, 2016, in the journal BMC Infectious Diseases.

Related Links:
Northern Ontario School of Medicine
Fisher Scientific
Cepheid
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.